ArticleCancers2020

Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Alex Claveria-Cabello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.